BRAF is a therapeutic target in aggressive thyroid carcinoma.

  title={BRAF is a therapeutic target in aggressive thyroid carcinoma.},
  author={Giuliana Salvatore and Valentina De Falco and Paolo Salerno and Tito Claudio Nappi and Stefano Pepe and Giancarlo Troncone and Francesca Carlomagno and Rosa Marina Melillo and Scott M. Wilhelm and Massimo Santoro},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={12 5},
PURPOSE Oncogenic conversion of BRAF occurs in approximately 44% of papillary thyroid carcinomas and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is associated with an unfavorable clinicopathologic outcome. Our aim was to exploit BRAF as a potential therapeutic target for thyroid carcinoma. EXPERIMENTAL DESIGN We used RNA interference to evaluate the effect of BRAF knockdown in the human anaplastic thyroid carcinoma cell lines FRO and ARO carrying the… CONTINUE READING